LobbyingAlliance for Regenerative Medicine lobbying by quarter
Alliance for Regenerative Medicine's latest lobbying report covers Q2 2026, at $180K. The four quarters Q4 2025–Q3 2026 total $700K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Alliance for Regenerative Medicine
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $700K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $460K | 3 |
| Q1 2023 | $170K | 2 |
| Q2 2023 | $180K | 3 |
| Q3 2023 | $440K | 4 |
| Q4 2023 | $410K | 5 |
| Q1 2024 | $300K | 5 |
| Q2 2024 | $290K | 4 |
| Q3 2024 | $296.4K | 5 |
| Q4 2024 | $340K | 4 |
| Q1 2025 | $250K | 3 |
| Q2 2025 | $270K | 3 |
| Q3 2025 | $250K | 3 |
| Q4 2025 | $340K | 3 |
| Q1 2026 | $180K | 2 |
| Q2 2026 | $180K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$3.7M · 43 reports
- Medicare and Medicaid$630K · 14 reports
- Homeland security$25K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE46 reports
- HOUSE OF REPRESENTATIVES44 reports
- Centers For Medicare and Medicaid Services (CMS)26 reports
- Health & Human Services, Dept of (HHS)18 reports
- Food & Drug Administration (FDA)16 reports
- White House Office8 reports
- Natl Institutes of Health (NIH)5 reports
- Office of Management & Budget (OMB)4 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAlliance for Regenerative Medicine | $2.4M | 13 quarters |
| BGR Government Affairs | $1M | 15 quarters |
| Holland & Knight | $570K | 9 quarters |
| Avenue Solutions | $420K | 9 quarters |
| Foley Hoag | $16.4K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| BRENT ALAN DEL MONTE | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee | Q2 2026 |
| CHARLIE CHAPMAN | Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committee; LA, House Budget Committee; Staff Asst, House Ways and Means Committee; Intern, House Ways and Means Committee | Q2 2026 |
| CHRIS KELLY | Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn | Q2 2026 |
| DANIEL FARMER | Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space | Q2 2026 |
| JAMES WILLIAMS | Special Asst. to the Pres., WH Domestic Policy Council, 2019-2021; Economist, WH Council of Economic Advisors, 2017-2019 | Q2 2026 |
| JOEL D. BAILEY | COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall | Q2 2026 |
| JOHN STONE | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C | Q2 2026 |
| RAGHAV AGGARWAL | Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior | Q2 2026 |
| REMY LEIGH BRIM MASON | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz | Q2 2026 |
| ROBB WALTON | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes | Q2 2026 |
| MARVIN BENITO FIGUEROA | COS, Sen. Laphonza Butler; Dir. of Off. of Inter. Affairs and Ext. Affairs, HHS; Sen. Policy Adv., Leg. Asst., Leg. Aide, Leg. Corr., Sec. Edu. Grad. Fellow, Sen. Mark Warner; Intern, White House | Q1 2026 |
| MATTHEW FUENTES | LA - Senate Democratic Minority Leader Sen. Chuck Schumer; LA -Senate Democratic Majority Leader Sen. Chuck Schumer; Legislative Aide - Sen. Chuck Schumer; Research Assistant - Senate Finance Committee (Sen. Ron Wyden) | Q2 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | BGR Government Affairs | $60K |
| 07/17for Q2 | In-house | $120K |
| 04/20for Q1 | BGR Government Affairs | $60K |
| 04/16for Q1 | In-house | $120K |
| 01/20for Q4 2025 | In-house | $230K |
| 01/20for Q4 2025 | Avenue Solutions | $50K |
| 01/20for Q4 2025 | BGR Government Affairs | $60K |
| 01/12for Q1 | BGR Government Affairs | Under $5,000 |
| 01/12for Q4 2025 | BGR Government Affairs | $60K |
| 25/10/20for Q3 2025 | In-house | $140K |
| 25/10/20for Q3 2025 | Avenue Solutions | $50K |
| 25/10/20for Q3 2025 | BGR Government Affairs | $60K |
| 25/07/23for Q2 2025 | In-house | $160K |
| 25/07/21for Q2 2025 | Avenue Solutions | $50K |
| 25/07/21for Q2 2025 | BGR Government Affairs | $60K |
| 25/04/21for Q1 2025 | In-house | $140K |
| 25/04/21for Q1 2025 | Avenue Solutions | $50K |
| 25/04/21for Q1 2025 | BGR Government Affairs | $60K |
| 25/01/21for Q4 2024 | In-house | $200K |
| 25/01/21for Q4 2024 | Avenue Solutions | $50K |